Drug intelligence / Profile preview

Qingbugongxia

Development stage: Preclinical
Modality: Small Molecules
Administration: Oral

Overview

Qingbugongxia is a traditional Chinese medicine (TCM) prescription used in the treatment of "heat syndrome" affecting the lung and stomach in patients with sepsis. The formula is rooted in TCM theory, aiming to clear heat, supplement deficiency, and purge excess. It is not a single chemical entity but rather a multi-herbal compound formulation. Its mechanism of action involves modulation of inflammatory responses and immune regulation according to TCM principles; however, specific molecular targets or pharmacological mechanisms are not well characterized by Western standards. Clinical studies have been registered to evaluate its therapeutic effect for sepsis-related syndromes[1].

Brand names: Qingbugongxia
Other names: Qingbugongxia prescription清补攻下方

Beyond the preview

Go deeper on Qingbugongxia.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qingbugongxia.

Explore the full profile